ZA201205167B - Antibody formulation and therapeutic regimens - Google Patents
Antibody formulation and therapeutic regimensInfo
- Publication number
- ZA201205167B ZA201205167B ZA2012/05167A ZA201205167A ZA201205167B ZA 201205167 B ZA201205167 B ZA 201205167B ZA 2012/05167 A ZA2012/05167 A ZA 2012/05167A ZA 201205167 A ZA201205167 A ZA 201205167A ZA 201205167 B ZA201205167 B ZA 201205167B
- Authority
- ZA
- South Africa
- Prior art keywords
- therapeutic regimens
- antibody formulation
- antibody
- formulation
- regimens
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000011285 therapeutic regimen Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29538710P | 2010-01-15 | 2010-01-15 | |
| US42205910P | 2010-12-10 | 2010-12-10 | |
| PCT/US2011/020985 WO2011088120A1 (en) | 2010-01-15 | 2011-01-12 | Antibody formulation and therapeutic regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201205167B true ZA201205167B (en) | 2013-03-27 |
Family
ID=43858045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/05167A ZA201205167B (en) | 2010-01-15 | 2012-07-11 | Antibody formulation and therapeutic regimens |
Country Status (38)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| EP2523688B1 (en) | 2010-01-15 | 2017-10-11 | Kirin-Amgen, Inc. | Antibody formulation and therapeutic regimens |
| PL2531218T3 (pl) | 2010-02-04 | 2019-05-31 | Csl Behring Ag | Preparat immunoglobuliny |
| CN102906118B (zh) | 2010-05-20 | 2017-07-28 | 埃博灵克斯股份有限公司 | 与her3相关的生物材料 |
| KR20130110169A (ko) | 2010-09-22 | 2013-10-08 | 암젠 인크 | 담체 면역글로뷸린 및 이것의 용도 |
| SG193963A1 (en) * | 2011-04-07 | 2013-11-29 | Glaxosmithkline Llc | Formulations with reduced viscosity |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20140234330A1 (en) * | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| EP3492099A1 (en) * | 2011-11-23 | 2019-06-05 | Amgen Inc. | Administration of alpha4beta7 hetero-dimer-specific antibody |
| MX362191B (es) * | 2012-03-07 | 2019-01-08 | Lilly Co Eli | Formulacion de anticuerpo il-17. |
| ES2622558T3 (es) | 2012-05-14 | 2017-07-06 | Novo Nordisk A/S | Soluciones proteínicas estabilizadas |
| SG10201805015TA (en) | 2013-03-15 | 2018-07-30 | Amgen Inc | Methods for treating crohn's disease using an anti-il23 antibody |
| US20160060337A1 (en) | 2013-03-15 | 2016-03-03 | Amgen Inc. | Methods for treating psoriasis using an anti-il-23 antibody |
| CN106456751B (zh) * | 2014-03-31 | 2021-02-02 | 安姆根K-A有限公司 | 治疗指甲和头皮银屑病的方法 |
| JP6671298B2 (ja) | 2014-05-16 | 2020-03-25 | アムジェン インコーポレイテッド | Ｔｈ１及びｔｈ２細胞集団を検出するためのアッセイ |
| CN106573059A (zh) * | 2014-08-26 | 2017-04-19 | 麒麟-安姆根有限公司 | 接受过抗TNF‑α抗体疗法的银屑病患者的治疗方法 |
| EP3193171B1 (en) * | 2014-09-10 | 2019-05-29 | NOF Corporation | Use of a protein adsorption inhibitor and method for inhibiting protein adsorption |
| CA2968915A1 (en) | 2014-12-03 | 2016-06-09 | Csl Behring Ag | Pharmaceutical product with increased stability comprising immunoglobulins |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| JP6909208B2 (ja) | 2015-09-17 | 2021-07-28 | アムジェン インコーポレイテッド | Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 |
| WO2017077391A2 (en) | 2015-11-04 | 2017-05-11 | Astrazeneca Ab | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
| WO2017112536A1 (en) | 2015-12-22 | 2017-06-29 | Amgen Inc. | Ccl20 as a predictor of clinical response to il23-antagonists |
| EP3446178A4 (en) | 2016-04-19 | 2020-01-22 | Sage Electrochromics, Inc. | ELECTROCHROMIC DEVICE COMPRISING A TRANSPARENT CONDUCTIVE OXIDE LAYER AND AN OMNIBUS BAR AND ITS FORMING METHOD |
| GB201612043D0 (en) * | 2016-07-11 | 2016-08-24 | Crescendo Biologics Ltd | Composition for treatment of disorders |
| CA2974531A1 (en) * | 2017-07-26 | 2019-01-26 | Michael Giroux | Safety anchor and roof vent |
| GB201719447D0 (en) | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| JP2021532176A (ja) | 2018-07-13 | 2021-11-25 | アストラゼネカ・コラボレイション・ベンチャーズ・リミテッド・ライアビリティ・カンパニーAstrazeneca Collaboration Ventures, Llc | ブラジクマブによる潰瘍性大腸炎の処置 |
| UA128098C2 (uk) | 2019-02-18 | 2024-04-03 | Елі Ліллі Енд Компані | Водна фармацевтична композиція антитіла проти il-17a |
| WO2021050563A1 (en) * | 2019-09-09 | 2021-03-18 | The Rockefeller University | Antibody treatment for lesional tissue of hidradenitis suppurativa |
| CN114401993A (zh) * | 2019-09-11 | 2022-04-26 | 博世健康爱尔兰有限公司 | 使用il-17ra抗体治疗非酒精性脂肪肝疾病(nafld)的方法 |
| MX2022010120A (es) * | 2020-02-18 | 2022-09-05 | Amgen Inc | Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos. |
| CN112891530B (zh) * | 2020-06-19 | 2021-08-24 | 北京东方百泰生物科技股份有限公司 | 一种抗il-17ra单克隆抗体的注射制剂 |
| CA3218343A1 (en) * | 2021-05-12 | 2022-11-17 | Anaptysbio, Inc. | Antibody composition |
| EP4537345A1 (en) * | 2022-06-06 | 2025-04-16 | Fusion Pharmaceuticals Inc. | Methods of dosing therapeutic agents |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1000835A (en) | 1911-06-19 | 1911-08-15 | Stewart A Minnick | Calipers. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL83878A (en) | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
| IL98078A0 (en) | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| GB8807803D0 (en) | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
| AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| IL94039A (en) | 1989-08-06 | 2006-09-05 | Yeda Res & Dev | Antibodies to tbp - 1 and their use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| ES2238070T3 (es) | 1989-04-21 | 2005-08-16 | Amgen Inc. | Receptor del tnf, proteina ligante del tnf y adn codante para estos. |
| DE3922089A1 (de) | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
| DK0398327T4 (da) | 1989-05-18 | 2013-04-15 | Yeda Res & Dev | Tumornekrosefaktor-bindende protein, dets oprensning og antistoffer dertil |
| IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
| US5703088A (en) | 1989-08-21 | 1997-12-30 | Beth Israel Deaconess Medical Center, Inc. | Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses |
| CA2485553A1 (en) | 1989-09-05 | 1991-03-21 | Immunex Corporation | Tumor necrosis factor - .alpha. and - .beta. receptors |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| EP1132471A3 (de) | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
| JPH03127800A (ja) | 1989-10-13 | 1991-05-30 | Teijin Ltd | 腫瘍壊死因子活性抑制物質 |
| DE69022559T2 (de) | 1989-12-13 | 1996-05-02 | Yeda Res & Dev | Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I). |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5136021A (en) | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US6458360B1 (en) | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
| GB2243569A (en) | 1990-05-02 | 1991-11-06 | Andrew Langdon | Brush with timer |
| ATE309376T1 (de) | 1990-06-28 | 2005-11-15 | Hoechst Ag | Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung |
| WO1992001002A1 (en) | 1990-07-11 | 1992-01-23 | Teijin Limited | Tumor necrosis factor activity inhibitor and production thereof |
| SG63617A1 (en) | 1991-01-18 | 1999-03-30 | Amgen Boulder Inc | Methods for treating tumar necrosis factor mediated diseases |
| DK0575545T3 (da) | 1991-03-15 | 2003-09-15 | Amgen Inc | Pegylering af polypeptider |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| EP0611302B1 (en) | 1991-10-15 | 2000-03-29 | MULLARKEY, Michael F. | Receptors for treating late phase inflammatory responses |
| US5716805A (en) | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
| EP1239043A3 (en) | 1992-03-30 | 2003-01-02 | Immunex Corporation | Fusion proteins comprising tumour necrosis factor receptor |
| DK0639079T3 (da) | 1992-04-30 | 2000-06-13 | Amgen Inc | Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme |
| JPH05312248A (ja) | 1992-05-08 | 1993-11-22 | Nissan Motor Co Ltd | シフトレバー装置 |
| EP0620739A4 (en) | 1992-09-15 | 1997-01-15 | Immunex Corp | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists. |
| US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
| DK0817847T4 (da) | 1995-03-23 | 2009-10-05 | Immunex Corp | IL-17-receptor |
| US6680057B1 (en) | 1995-03-23 | 2004-01-20 | Immunex Corporation | Methods of treating autoimmune disease by administering interleukin-17 receptor |
| EP1591529A3 (en) | 1995-07-19 | 2005-11-09 | Genetics Institute, LLC | Human CLTA-8 and uses of CTLA-8-related proteins |
| US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| US6406867B1 (en) | 1996-08-16 | 2002-06-18 | Human Genome Sciences, Inc. | Antibody to human endokine alpha and methods of use |
| AU7408998A (en) | 1996-11-27 | 1998-06-22 | Immunex Corporation | Method of regulating nitric oxide production |
| PT1500329E (pt) | 1996-12-03 | 2012-06-18 | Amgen Fremont Inc | Anticorpos humanos que se ligam especificamente ao tnf alfa humano |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6482923B1 (en) | 1997-09-17 | 2002-11-19 | Human Genome Sciences, Inc. | Interleukin 17-like receptor protein |
| ES2333385T3 (es) | 1997-09-17 | 2010-02-19 | Human Genome Sciences, Inc. | Proteina del tipo de interleuquina-17. |
| EP2333069A3 (en) | 1998-05-15 | 2011-09-14 | Genentech, Inc. | Therapeutic uses of IL-17 homologous polypeptides |
| JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| PL354987A1 (en) | 1999-10-04 | 2004-03-22 | Chiron Corporation | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| TWI322154B (en) | 2000-03-16 | 2010-03-21 | Amgen Inc | Il-17 receptor like molecules and uses thereof |
| AU2001247545A1 (en) | 2000-03-16 | 2001-09-24 | Amgen Inc. | Il-17 receptor like molecules and uses thereof |
| US20030180255A1 (en) | 2000-08-24 | 2003-09-25 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| MXPA03003407A (es) | 2000-10-18 | 2004-05-04 | Immunex Corp | Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17. |
| WO2003072060A2 (en) | 2002-02-27 | 2003-09-04 | Immunex Corporation | Polypeptide formulation |
| WO2004002519A1 (en) | 2002-06-27 | 2004-01-08 | Smithkline Beecham Corporation | Methods of treating or preventing ibd with il-18 |
| EP1517921B1 (en) | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
| DE10333317A1 (de) | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| US20050070460A1 (en) | 2003-08-05 | 2005-03-31 | 3M Innovative Properties Company | Infection prophylaxis using immune response modifier compounds |
| GB0321703D0 (en) * | 2003-09-16 | 2003-10-15 | Imerys Minerals Ltd | Surface modified fillers for polymer resin compositions |
| US20070184050A1 (en) | 2003-12-25 | 2007-08-09 | Kirin Beer Kabushiki Kaisha | Stable water-based medicinal preparation containing antibody |
| IL159670A0 (en) | 2003-12-31 | 2004-06-01 | Yeda Res & Dev | Use of il-18 binding protein in inflammations |
| KR20070085199A (ko) | 2004-06-04 | 2007-08-27 | 디자이너 몰레큘스 인코퍼레이티드 | 자유-라디칼에 경화되는 폴리에스테르 및 그 사용 방법 |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| BRPI0608210A2 (pt) | 2005-02-14 | 2010-11-09 | Wyeth Corp | métodos de diagnóstico de um distúrbio relacionado com il-17f em um indivìduo e de seleção de compostos capazes de inibirem a ligação de il-17f em il-17r, uso de um antagonista de il-17f, composição farmacêutica, e, adjuvante de vacina |
| EP3673919A1 (en) | 2005-06-14 | 2020-07-01 | Amgen Inc. | Self-buffering protein formulations |
| NZ564843A (en) | 2005-08-03 | 2012-05-25 | Immunogen Inc | Immunoconjugate formulations comprising an immunoconjugate and an excipient in a buffered aqueous solution |
| EP1916997B1 (en) | 2005-08-05 | 2018-04-18 | Amgen Inc. | Stable aqueous protein pharmaceutical formulations and their preparation |
| BRPI0615297A2 (pt) | 2005-09-01 | 2011-05-17 | Schering Corp | antagonistas de il-23 e de il-17 para tratar doença inflamatória ocular auto-imune e seus usos |
| WO2007047738A1 (en) | 2005-10-18 | 2007-04-26 | Zymogenetics, Inc. | Il-17c antagonists and methods of using the same |
| PT3225233T (pt) | 2005-11-01 | 2019-10-24 | Wyeth Llc | Solução de cloreto de sódio para reconstituição de fármacos. |
| EP1977763A4 (en) * | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | STABILIZER PREPARATION CONTAINING ANTIBODIES |
| AU2007212147A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| UA99716C2 (ru) * | 2006-10-02 | 2012-09-25 | Кирин-Амген Инк. | Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra) |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| EP2064237A2 (en) | 2006-10-18 | 2009-06-03 | ZymoGenetics, Inc. | Il-17c antagonists and methods of using the same |
| CA2672902C (en) * | 2006-12-21 | 2012-11-27 | Amgen Inc. | Formulations |
| FR2910324B1 (fr) | 2006-12-21 | 2009-03-06 | Biomerieux Sa | Nouveau medicament pour le traitement d'un cancer gastrique |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| CA2679588A1 (en) | 2007-03-26 | 2008-10-02 | Zymogenetics, Inc. | Soluble il-17ra/rc fusion proteins and related methods |
| WO2008156709A1 (en) * | 2007-06-13 | 2008-12-24 | Amgen Inc. | Il-17 heteromeric receptor complex |
| WO2009006301A2 (en) | 2007-06-29 | 2009-01-08 | Battelle Memorial Institute | Protein stabilization |
| AU2008289225A1 (en) | 2007-08-17 | 2009-02-26 | Amgen Inc. | Formulations of antibodies and Fc-fusion molecules using polycations |
| WO2009136976A2 (en) | 2008-02-21 | 2009-11-12 | Amgen Inc | Il-17ra-il-17rb antagonists and uses thereof |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| EP2523688B1 (en) * | 2010-01-15 | 2017-10-11 | Kirin-Amgen, Inc. | Antibody formulation and therapeutic regimens |
| EP3792281A1 (en) | 2010-10-08 | 2021-03-17 | Novartis AG | Methods of treating psoriasis using il-17 antagonists |
| AR083546A1 (es) | 2010-10-25 | 2013-03-06 | Genentech Inc | Tratamiento de inflamacion gastrointestinal, soriasis y asma |
| US20140044727A1 (en) * | 2011-04-07 | 2014-02-13 | Glaxosmithkline Llc | Formulations with reduced viscosity |
| SG193963A1 (en) * | 2011-04-07 | 2013-11-29 | Glaxosmithkline Llc | Formulations with reduced viscosity |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| CN106456751B (zh) | 2014-03-31 | 2021-02-02 | 安姆根K-A有限公司 | 治疗指甲和头皮银屑病的方法 |
| CN106573059A (zh) | 2014-08-26 | 2017-04-19 | 麒麟-安姆根有限公司 | 接受过抗TNF‑α抗体疗法的银屑病患者的治疗方法 |
-
2011
- 2011-01-12 EP EP11705713.3A patent/EP2523688B1/en active Active
- 2011-01-12 HU HUE17195530A patent/HUE046670T2/hu unknown
- 2011-01-12 MA MA35124A patent/MA33989B1/fr unknown
- 2011-01-12 PL PL11705713T patent/PL2523688T3/pl unknown
- 2011-01-12 SI SI201131792T patent/SI3295957T1/sl unknown
- 2011-01-12 CA CA2787128A patent/CA2787128C/en active Active
- 2011-01-12 PT PT117057133T patent/PT2523688T/pt unknown
- 2011-01-12 RS RS20171311A patent/RS56781B1/sr unknown
- 2011-01-12 HU HUE11705713A patent/HUE035618T2/en unknown
- 2011-01-12 JP JP2012549047A patent/JP5743234B2/ja active Active
- 2011-01-12 RS RS20191335A patent/RS59743B1/sr unknown
- 2011-01-12 HR HRP20171939TT patent/HRP20171939T1/hr unknown
- 2011-01-12 IN IN6720DEN2012 patent/IN2012DN06720A/en unknown
- 2011-01-12 SG SG10201604093XA patent/SG10201604093XA/en unknown
- 2011-01-12 UA UAA201209849A patent/UA112288C2/uk unknown
- 2011-01-12 AU AU2011205402A patent/AU2011205402B2/en active Active
- 2011-01-12 PT PT171955305T patent/PT3295957T/pt unknown
- 2011-01-12 KR KR1020127021299A patent/KR101766936B1/ko active Active
- 2011-01-12 US US13/521,999 patent/US8883151B2/en active Active
- 2011-01-12 EA EA201290653A patent/EA031209B9/ru not_active IP Right Cessation
- 2011-01-12 WO PCT/US2011/020985 patent/WO2011088120A1/en not_active Ceased
- 2011-01-12 SG SG2012051108A patent/SG182468A1/en unknown
- 2011-01-12 EP EP19189613.3A patent/EP3632466A1/en not_active Withdrawn
- 2011-01-12 MX MX2012008213A patent/MX349856B/es active IP Right Grant
- 2011-01-12 DK DK17195530.5T patent/DK3295957T3/da active
- 2011-01-12 LT LTEP17195530.5T patent/LT3295957T/lt unknown
- 2011-01-12 EP EP17195530.5A patent/EP3295957B1/en active Active
- 2011-01-12 NO NO11705713A patent/NO2523688T3/no unknown
- 2011-01-12 DK DK11705713.3T patent/DK2523688T3/en active
- 2011-01-12 EA EA201891433A patent/EA201891433A3/ru unknown
- 2011-01-12 MY MYPI2016001562A patent/MY182680A/en unknown
- 2011-01-12 LT LTEP11705713.3T patent/LT2523688T/lt unknown
- 2011-01-12 CN CN201180012846.1A patent/CN102821787B/zh active Active
- 2011-01-12 PL PL17195530T patent/PL3295957T3/pl unknown
- 2011-01-12 SI SI201131350T patent/SI2523688T1/en unknown
- 2011-01-12 ES ES11705713.3T patent/ES2652637T3/es active Active
- 2011-01-12 NZ NZ601125A patent/NZ601125A/en unknown
- 2011-01-12 ES ES17195530T patent/ES2753216T3/es active Active
- 2011-01-12 PE PE2012001003A patent/PE20121691A1/es active IP Right Grant
- 2011-01-12 PH PH1/2012/501364A patent/PH12012501364A1/en unknown
- 2011-01-12 BR BR112012017150-0A patent/BR112012017150B1/pt active IP Right Grant
- 2011-01-14 AR ARP110100123A patent/AR079903A1/es not_active Application Discontinuation
- 2011-01-14 TW TW100101536A patent/TWI554282B/zh active
-
2012
- 2012-06-24 IL IL220602A patent/IL220602B/en active IP Right Grant
- 2012-06-26 TN TNP2012000335A patent/TN2012000335A1/en unknown
- 2012-07-11 ZA ZA2012/05167A patent/ZA201205167B/en unknown
- 2012-07-13 CL CL2012001966A patent/CL2012001966A1/es unknown
- 2012-08-10 CO CO12135074A patent/CO6640206A2/es unknown
- 2012-08-10 CR CR20120419A patent/CR20120419A/es unknown
-
2014
- 2014-09-29 US US14/499,691 patent/US10072085B2/en active Active
- 2014-12-05 JP JP2014247218A patent/JP2015052017A/ja active Pending
-
2015
- 2015-04-21 AU AU2015202023A patent/AU2015202023B2/en active Active
-
2017
- 2017-08-18 AU AU2017216579A patent/AU2017216579A1/en not_active Abandoned
-
2018
- 2018-01-09 CY CY20181100022T patent/CY1119852T1/el unknown
- 2018-08-02 US US16/053,564 patent/US10808033B2/en active Active
-
2019
- 2019-11-04 CY CY20191101143T patent/CY1122466T1/el unknown
-
2020
- 2020-09-08 US US17/015,029 patent/US11505612B2/en active Active
-
2022
- 2022-10-11 US US18/045,534 patent/US20230192873A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201205167B (en) | Antibody formulation and therapeutic regimens | |
| PL3333188T3 (pl) | Przeciwciała anty-ngf i ich zastosowanie | |
| EP2542086A4 (en) | COMPOUNDS AND ITS THERAPEUTIC USE | |
| IL221511A (en) | Arilatriazolones associated with bis aryl and their use | |
| EP2552953A4 (en) | FRIZZLED-BINDING SUBSTANCES AND ITS USES | |
| ZA201403372B (en) | Therapeutic agents and uses thereof | |
| ZA201208173B (en) | Peptices and their use | |
| EP2718283A4 (en) | INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | |
| IL223667B (en) | 4a100s antibodies and medical uses thereof | |
| ZA201307641B (en) | Human tissue factor antibody and uses thereof | |
| ZA201300930B (en) | St-246 liquid formulations and methods | |
| PT2568806T (pt) | Regimes terapêuticos | |
| PT2521445T (pt) | Formulação e utilização da mesma | |
| GB201011411D0 (en) | Therapeutic compounds and their use | |
| PT2563806E (pt) | Leucolectinas humanas e suas utilizações | |
| AP2014007616A0 (en) | Agrochemical formulation and use thereof | |
| EP2657236A4 (en) | NEW 2-ALKYNYL-N9-PROPARGYLADENINE AND ITS MEDICAL USE | |
| GB201003741D0 (en) | Methods and therapeutic compositions | |
| GB201012660D0 (en) | Inhaler and formulation | |
| GB201002451D0 (en) | Pharmaceutical comopitions and devices | |
| GB201112578D0 (en) | Pharmaceutical preparation and use | |
| GB201019972D0 (en) | Drug composition and its use in therapy | |
| GB201021425D0 (en) | Drug composition and its use in therapy | |
| GB201019971D0 (en) | Drug composition and its use in therapy |